Rezultati pretraživanja
  1. 1. velj
  2. 30. sij
    Odgovor korisniku/ci

    The Dec call mentioned the. 3-73 clinical is enrolled with the most patients of any previous alzheimers clinical & Anavex is looking for other sites to continue expanding enrollment. I certainly hope the outstanding results continue for patients

  3. 30. sij
  4. 28. sij
  5. 11. pro 2019.

    : Corp, que diseña y fabrica equipos de dispensación para adhesivos, selladores y recubrimientos industriales y de consumo; Oxford Industries; , fabricante estadounidense de fotomask de semiconductores, y reportan el día de hoy.

  6. 23. stu 2019.
  7. 16. ruj 2019.

    preliminary data seems positive. Yes, it's preliminary and anything can happen between now and the final data results, but the important thing is that there is currently no effective treatment for .

  8. 4. ožu 2019.
  9. 26. velj 2019.

    20 hospitales de todo el territorio nacional ponen en marcha la segunda fase del ensayo clínico 2-73, el único estudio de Europa para pacientes de con asociada

  10. 7. velj 2019.

    Reports Fiscal 2019 Q1 Financial Results And Provides Clinical Study Updates, stock reduces -1.92%

  11. 25. lis 2018.

    Are you going to cover @ ? I always look forward to your insights.

  12. 19. lis 2018.

    Life Sciences Corp. ( ), approves Anavex Life Sciences' IND for Phase 2 trial of ANAVEX2-73; upgraded to buy.

  13. 25. ruj 2018.

    Great story on current new clinical trial with / also great to see talking opportunities for early interventions - if you want to know more on this drug trial

  14. 10. kol 2018.
  15. 3. srp 2018.

    receives approval to initiate Phase 2b/3 clinical trial of AVANEX 2-73, stock surges +27.82%,

  16. 12. lip 2018.

    one of my favorites!! why? Reason 4: Patient 101011, THERAPEUTIC RESPONSE UNEXPECTED: wife thinks patient is a bit more cheerful

  17. 21. stu 2017.

    2-73 presses forward based on positive cognitive findings in 6 patients. Phase 2/3 trial should be announced by the end of this year, CEO Christopher Missling says.

  18. 20. stu 2017.

    2-73 story should be posted this evening. I will link to it as soon as it is.

  19. 16. stu 2017.
    Odgovor korisniku/ci

    Looking forward to it! Your post CTAD 2016 article was one of the best/most comprehensive write-ups on 's very promising 's /CNS therapy to date.

  20. 16. stu 2017.

    I'm working on a story about 2-73, a sigma 1 receptor agonist in early phase development for 's. In the meantime, anyone can look at the slides presented at . Kudos to Anavex for publicly posting research material.

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.